What personal data we collect and why we collect it
Comments
When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection.
An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.
Media
If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.
Contact forms
Cookies
If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year.
If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser.
When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select “Remember Me”, your login will persist for two weeks. If you log out of your account, the login cookies will be removed.
If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.
Embedded content from other websites
Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website.
These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.
Analytics
Who we share your data with
How long we retain your data
If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue.
For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.
What rights you have over your data
If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.
Where we send your data
Visitor comments may be checked through an automated spam detection service.
Your contact information
Additional information
How we protect your data
What data breach procedures we have in place
What third parties we receive data from
What automated decision making and/or profiling we do with user data
永鼎醫藥母公司YD Biopharma(開曼)順利完成與美國公開交易特殊目的收購公司Breeze的企業合併,正式成立YD Bio Ltd,今(29)日在美國Nasdaq全球市場掛牌上市,普通股與認股權證交易代碼為「YDES」與「YDESW」。YD Bio Ltd是一家採用甲基化的癌症檢測技術與眼科創新的生物科技公司,承襲永鼎的研發實力並拓展國際市場。
YD Bio Ltd宣布,PIPE融資已隨企業合併全額完成。交易在扣除相關費用後預計將為公司帶來超過1,150萬美元,約新台幣3.5億,支持公司未來營運及發展。這項業務合併和PIPE融資完成標誌公司發展的重要一步。品牌定位為生技產業的新興領導者,在多個快速成長的醫療市場中具備強勁的增長潛力。透過進入公開市場,將能加速創新、擴大產能,並推動突破性技術的開發與商業化。
YD Bio Ltd表示,核心商業模式聚焦於與生技製藥公司建立策略性合作關係,將創新技術轉化為具商業價值的藥物與癌症檢測診斷。由生醫領域資深專家沈協聰博士擔任董事長,憑藉超過30年的生醫產業經驗,致力於推動涵蓋癌症檢測、再生醫學與臨床試驗支持的多元創新醫療方案。
YD Bio Ltd核心業務聚焦於三大領域,包括血液癌症檢測、幹細胞與外泌體眼科療法、臨床試驗與輔助服務。血液癌症檢測透過與愛立基生醫合作夥伴EG BioMed的獨家授權協議,透過獨有的DNA甲基化技術用於乳癌復發與胰臟癌早期診斷。目前已透過EG BioMed的CLIA認證實驗室以實驗室開發檢測推進,並計畫向FDA申請批准。